Thieler Law Corp advises investors with losses exceeding $100,000 of the January 14, 2020 lead plaintiff deadline in a class action lawsuit filed against Lipocine Inc (NASDAQ: LPCN) (“Lipocine” or “the Company”). The suit is pending in the U.S. District Court for the District of Utah and investors, who purchased Lipocine Inc securities between March 27, 2019 and November 8, 2019, have until January 14, 2020 to move for lead plaintiff. You do not need to move for lead plaintiff to be a member of the Class.

If you purchased Lipocine Inc securities during the Class Period, and have losses over $100,000, you may contact Thieler Law Corp by calling at (619) 377 - 4324 or emailing mail@thielerlaw.com . No class has been certified in this case, and if your losses are less than $100,000 you are still a member of the class.

The complaint alleges that during the Class Period defendants made false and misleading statements and/or allegedly failed to disclose that the results from Lipocine’s clinical studies of TLANDO were insufficient to demonstrate the drug’s efficacy;  accordingly, Lipocine’s third New Drug Application for TLANDO was highly likely to be found deficient by the FDA; and as a result, defendants’ statements regarding Lipocine’s business, operations, and prospects, were materially false and misleading. When the true details entered the market, the lawsuit claims that investors suffered damages.

On November 11, 2019, the Company revealed receipt of a Complete Response Letter ("CRL") from the U.S. Food and Drug Administration regarding its New Drug Application for TLANDO, Lipocine's product candidate for testosterone replacement therapy. Lipocine advised investors, inter alia, that "[t]he CRL identified one deficiency stating the efficacy trial did not meet the three secondary endpoints for maximal testosterone concentrations."

Following this news, NASDAQ: LPCN fell during intraday trading on November 11, 2019, harming investors.

If you were negatively impacted by your investment in Lipocine Inc securities between March 27, 2019 and November 8, 2019 and would like to learn more about this lawsuit and your ability to participate as a lead plaintiff, please contact us for your no-cost evaluation.

Thieler Law Corp purchases advertisements on search engines, social media sites and other websites. If you send us information, note that does not create an attorney-client relationship with the firm. Materials are provided for informational purposes only and do not constitute legal advice. We are only licensed to practice law in Germany. We are neither licensed nor qualified to render advice on US Federal or State law.

Thieler Law Corp

2534 State Street - Suite 406,

San Diego, CA 92101

by

email: mail@thielerlaw.com

or

telephone at +1 (619) 377 - 4324

or

visit our website http://www.thielerlaw.com/

or

Facsimile: +1 (619) 785 – 3185